Regenerative Ocular Surface Therapies
Restoring the biological environment of the ocular surface
In severe or refractory ocular surface disease, conventional lubrication and anti-inflammatory therapy may be insufficient to restore epithelial integrity, corneal innervation and tissue homeostasis.
Regenerative ocular surface therapies aim to promote epithelial healing, neurotrophic recovery, extracellular matrix restoration and biological tear-film support.
They include blood-derived biologic eye drops, neuro-regenerative therapies, amniotic-derived biologic products, epithelial healing agents, extracellular matrix-regenerating therapies and emerging cell-based or cell-free regenerative approaches.
These treatments should not be considered as isolated alternatives to conventional or interventional therapy. They should be integrated into a mechanism-based and multimodal treatment strategy, according to the tissue compartment that requires restoration and the pathophysiological mechanisms identified in each patient.
The objective is not simply to lubricate or protect the ocular surface, but to restore its biological capacity for repair and homeostasis.
Blood-derived biologic eye drops
- Autologous serum
- PRP
- PRGF
- Platelet lysate
- Allogeneic serum
- Umbilical cord serum
Neuro-regenerative therapies
- Cenegermin / recombinant human NGF
- Emerging neurotrophic factors and peptides
Epithelial regeneration
- Topical insulin
- Thymosin β4
- Growth-factor and peptide-based approaches
Amniotic-derived regenerative therapies
- Amniotic membrane extracts
- Amniotic biologic derivatives
- Soluble regenerative products derived from amniotic tissue
Extracellular matrix regeneration
- RGTA / heparan-sulfate mimetics
- Matrix-supporting regenerative agents
Cellular and tissue-based therapies
- Limbal stem-cell therapies
- Mesenchymal stromal/stem-cell approaches
Emerging cell-free regenerative therapies
- Extracellular vesicles
- Exosomes
- Stem-cell secretome-derived therapies